Half the population experiences these conditions. Many are universal, recurring, and clinically significant. Yet in the eyes of too many investors, women’s health therapeutics remain “optional.”
In this episode of Blindspot Capital, I sit down with Sabrina Johnson, President & CEO of Daré Bioscience, to unpack the misconceptions holding back investment in women’s health from contraception to menopause to vaginal health and explore how disciplined science can change the game.
In This Episode We Cover:
🟣 Why women’s health markets are larger and more recurrent than most investors realize
🟣 The false perception that women’s health conditions are “lifestyle” or “optional”
🟣 The reality of recruiting participants for women’s health trials (and why stigma isn’t a barrier)
🟣 What scientific credibility really looks like in biotech and how to protect it
🟣 The difference between medicine and marketing and why the distinction matters for investors
🟣 Why angel investors have a leadership opportunity in women’s health
Join 10,000+ readers of the FemmeHealth newsletter on Substack.
------------------------------
Why You Should Listen If you care about women’s health, biotech, or the intersection of science and capital, this is a clear-eyed look at the market opportunities hiding in plain sight and the leadership it will take to unlock them.
About Sabrina Johnson Sabrina Johnson is the President & CEO of Daré Bioscience, a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. Daré believes that innovation does not have to start from scratch.
The company’s goal is to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in women’s health and enhance outcomes and convenience, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Learn more Here
🎧 Listen now and share with someone who still thinks women’s health is “niche.”
📌 Watch on YouTube
